Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? by Chiefari, Eusebio et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Cancer
Open Access BMC Cancer  2002,  2 x Research article
Increased expression of AP2 and Sp1 transcription factors in human 
thyroid tumors: a role in NIS expression regulation?
Eusebio Chiefari1, Antonio Brunetti1, Franco Arturi1, Jean-Michel Bidart2, 
Diego Russo3, Martin Schlumberger2 and Sebastiano Filetti*4
Address: 1Department of Experimental and Clinical Medicine "G. Salvatore", University of Catanzaro, 88100 Catanzaro, Italy, 2Département de 
Biologie Clinique and Service de Médecine Nucléaire, Institut Gustave Roussy, 94805 Villejuif, France, 3Department of Pharmacobiological 
Sciences, University of Catanzaro, 88100 Catanzaro, Italy and 4Department of Clinical Sciences, University of Roma "La Sapienza", Roma, Italy
E-mail: Eusebio Chiefari - e.chiefari@tin.it; Antonio Brunetti - brunetti@unicz.it; Franco Arturi - arturi@unicz.it; Jean-
Michel Bidart - bidart@igr.fr; Diego Russo - d.russo@unicz.it; Martin Schlumberger - schlumbg@igr.fr; 
Sebastiano Filetti* - sebastiano.filetti@uniroma1.it
*Corresponding author
Abstract
Background: Sodium/iodide symporter (NIS) is a key protein in iodide transport by thyroid cells
and this activity is a prerequisite for effective radioiodide treatment of thyroid cancer. In the
majority of thyroid cancers, however, iodide uptake is reduced, probably as a result of decreased
NIS protein expression.
Methods: To identify the mechanisms that negatively affect NIS expression in thyroid tumors, we
performed electrophoresis mobility shift assays and immunoblot analysis of nuclear protein
extracts from normal and tumoral thyroid tissues from 14 unrelated patients.
Results: Two proteins closely related to the transcription factors AP2 and Sp1 were identified in
the nuclear extracts. Expression of both AP2 and Sp1 in nuclear extracts from thyroid tumors was
significantly higher than that observed in corresponding normal tissues.
Conclusion: These observations raise the possibility that NIS expression, and subsequently iodide
transport, are reduced in thyroid tumors at least in part owing to alterations in the binding activity
of AP2 and Sp1 transcription factors to NIS promoter.
Background
Because the majority of differentiated thyroid carcinomas
and their metastases concentrate iodide less efficiently
than normal thyroid tissue, diagnostic and therapeutic
procedures based on the use of radioiodide are largely in-
effective in these cases [1]. Recently reports suggest that
thyroid tumors are characterized by reduced expression of
both the Na+/I- symporter (NIS) protein and its gene [1–
4]. Improvement of NIS gene expression and function
might therefore represent an important step toward in-
creasing the effectiveness of radioiodide treatment in
these patients.
Recently, the 5'-flanking DNA sequence of the human NIS
gene has been analyzed by several groups [5–11]. These
studies have led to the detection and characterization of
DNA regulatory proteins that seem to play important
roles in regulating the transcription of this gene. To shed
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greater light on the molecular basis of NIS deficiency in
thyroid cancer cells, we analyzed the regulatory region of
the NIS gene using a gel retardation assay combined with
immunoblot analysis. Our findings indicate that at least
two proteins from human thyroid tissue bind to DNA be-
tween nucleotides -454 to -242. DNA binding activity to
these sites was markedly increased in tumoral tissue com-
pared to normal tissue, suggesting that this alteration may
cause reduced promoter activity of the Na+/I- symporter
gene and determine I- uptake deficiency in human thyroid
tumors.
Methods
The study was conducted on thyroid tissues from four un-
related patients with hypofunctioning thyroid adenomas
(2 males and 2 females, age ranging from 31 to 46 years
with no history of thyroid autoimmunity) and ten with
differentiated thyroid carcinomas (7 papillary and 3 fol-
licular thyroid carcinomas, 3 males and 7 females, age
ranging from 30 to 68 years with no history of thyroid au-
toimmunity) were studied. This study was approved by
the local ethical committee. The specimens had been col-
lected intraoperatively and frozen in liquid nitrogen. Tu-
mor tissue, as well as healthy surrounding tissue, was
analyzed for each patient. The levels of the NIS mRNA
were assessed by a semi-quantitative RT-PCR based meth-
od, as previously described [12].
Nuclear extracts were prepared from 100 mg of human
thyroid tissue following the procedure of Dignam et al., as
previously described [13]. For each extract, an equal
number of nuclei were homogenized and final protein
concentrations in the extracts were determined using the
colorimetric method of Bradford [14].
To obtain probe DNA for gel retardation assays, we used a
clone containing 1.4 Kb of 5' genomic sequence for the
NIS promoter, containing the minimal promoter activity
[5,6], which was kindly provided by Dr. Loos. The DNA
was digested into five fragments (of 287, 37, 542, 321 and
212 bp) with Ava II and end-labeled with (32P)dATP us-
ing DNA polymerase I (Amersham Pharmacia Biotech Ita-
lia, Cologno Monzese, Milan, Italy) [15]. Binding
reactions were performed as previously described [13].
The synthetic polynucleotide poly(dI-dC) was used as
competitor DNA to detect non specific DNA binding pro-
teins in the nuclear extracts. Competition studies were
performed with unlabeled 22-mer double stranded oligo-
nucleotides containing a consensus binding site for tran-
scription factors CREB, Sp1, AP1 and AP2 (Promega,
Milan, Italy) were used in competition studies.
Western blot analysis was performed as previously de-
scribed [13], using specific monoclonal anti-AP2 (Abcam
Limited, Cambridge, UK) or monoclonal anti-Sp1 anti-
body, (Santa Cruz Biotechnology, Inc., Segrate, Milan, It-
aly) antibodies. 1:2000 dilution of goat anti-rabbit IgG
antibody coupled to horseradish peroxidase was used as
secondary antibody.
Results
In a preliminary phase, nuclear extracts from normal thy-
roid tissue were incubated with 32P-labeled probes de-
rived from NIS regulation region and tested for the
presence of specific DNA-binding factors using a gel retar-
dation assay [8]. The experiments themselves were carried
out on both normal and tumoral thyroid tissue, as fol-
lows: a 10 µg aliquot of nuclear extracts was incubated
with labeled probe, in the presence of increasing amounts
of the synthetic polynucleotide poly(dI-dC). In vitro
DNA-binding activity within the extracts was reflected by
the presence of a retarded DNA-protein complex that was
detected with the probe derived from the NIS regulatory
region between -454 and -242 bp from the initiation site
(data not shown). The complex 'disappeared' progressive-
ly in the presence of an increasing excess of an unlabeled
form of the same probe (data not shown), thus demon-
strating the specificity of the binding activity.
Since DNA-binding sites for CREB, Sp1, AP1 and AP2
have been putatively described in the NIS promoter re-
gion [5], competitive binding studies were conducted
with synthetic 22-mer double stranded synthetic oligonu-
cleotides containing DNA-binding sites for each of these
transcription factors. The DNA binding activity of the nu-
clear extracts was annulled by the presence of competitive
binding sites for AP2 and Sp1, and preserved in the pres-
ence of oligonucleotides that included a CREB, AP1 or
mutated AP2 and Sp1 motif (Fig. 1).
We then examined nuclear proteins from normal and tu-
moral thyroid tissues. NIS promoter-DNA binding activity
in cold adenomatous tissue was slightly higher than that
observed in the corresponding normal tissue(data not
shown), whereas cancerous tissue was characterized by
significantly increased activity (approximately 5–10 fold)
with respect to corresponding controls (Fig. 2).
To verify the involvement of AP2 and Sp1 in this binding
activity, western blot analyses were performed using the
nuclear extracts of thyroid tissues from patients with thy-
roid adenomas and carcinomas. AP2 and Sp1 protein con-
tents in tumoral extracts were was significantly higher
than those of corresponding normal tissue (Fig. 3). We
did not find differences in AP2 and Sp1 expression be-
tween follicular and papillary thyroid carcinomas of our
series.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/35
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Discussion
Thyroid follicular cells have the unique ability to concen-
trate, organify and utilize iodide for the synthesis of thy-
roid hormones [16]. The rational for radioiodide
treatment of thyroid cancer is based on the iodide uptake
capacity of the gland, which is in large part mediated by
the NIS. However, NIS expression varies in thyroid cancer,
and in some cases it is completely absent so that some car-
cinomas cannot be treated with this modality [16]. A
greater understanding of the molecular mechanisms that
regulate NIS gene expression in human tissues could even-
tually lead to the elimination of this obstacle through the
development of new strategies to increase NIS expression
in thyroid tumors.
Defects in NIS function and/or expression have been re-
ported in patients with differentiated thyroid carcinomas
[1–4]. In a recent study of tumors of this type, we found
no evidence of NIS gene mutation [17]. Nonetheless, in
most cases, expression of the NIS protein and NIS mRNA
Figure 1
Competition for binding between thyroid nuclear proteins
and AP1 and Sp1 consensus oligonucleotides. 212 bp NIS
probe was 5' end-labeled and used in gel retardation assays
with 10 µg of thyroid tissue extracts. Lanes 1 and 8: probe
alone; lanes 2 and 9: probe plus nuclear extract from tumoral
thyroid tissue; lane 3: probe plus nuclear extract from
tumoral thyroid tissue in the presence of a 200-fold molar
excess of unlabeled AP2 consensus oligonucleotide; lane 4:
probe plus nuclear extract from tumoral thyroid tissue in the
presence of a 200-fold molar excess of unlabeled AP2 mutant
oligonucleotide, lane 5: probe plus nuclear extract from
tumoral thyroid tissue in the presence of a 200-fold molar
excess of unlabeled Sp1 consensus oligonucleotide; lane 6:
probe plus nuclear extract from tumoral thyroid tissue in the
presence of a 200-fold molar excess of unlabeled Sp1 mutant
oligonucleotide; lane 7: probe plus nuclear extract from
tumoral thyroid tissue in the presence of a 200-fold molar
excess of unlabeled AP2 and Sp1 consensus oligonucleotides.
In lanes 10 and 11 the probe was incubated with nuclear
extract from tumoral thyroid tissue were incubated in the
presence of a specific anti-AP2 (lane 10) or anti-Sp1 (lane 11)
antibody, respectively, thus inducing a supershift of the com-
plex. Arrows show the position of free (DNA) and bound
(DNA-P) probes.
Figure 2
Western blot analysis of nuclear extracts from normal and
cancer tissues, using monoclonal anti-AP2 and anti-Sp1 anti-
bodies. The cancerous tissues displayed higher levels of both
transcription factors, compared with normal thyroid tissues.
A representative of three separated assays is shown. N =
normal thyroid tissue; T = tumoral thyroid tissue.
Figure 3
Binding between the NIS promoter region and nuclear
extracts from thyroid tissues and correlation with NIS RNA
levels. The probe was incubated with nuclear extracts from
normal and tumoral thyroid tissues in the presence of 0.2 µg
poly(dI-dC) with, and DNA protein complexes were
resolved as shown in Fig. 1. Lanes: P, probe alone; N, probe
plus nuclear extract from normal thyroid tissue; T, probe
plus nuclear extract from cancer thyroid tissue. The levels of
the NIS mRNA were assessed by a semi-quantitative RT-PCR
based method, as previously described (12) and expressed as
mean ± S.E.M. of three different experiments.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/35
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levels were reduced with respect to normal adjacent tis-
sues. It is conceivable that the deficits we observed are the
result of alterations in factors which regulate the level of
NIS gene expression.
The promoter region of the human sodium/iodide-sym-
porter gene has recently been sequenced by several groups
[5–8]. Their reports indicate that the region contains sev-
eral nucleotide sequences representing consensus binding
sites for the transcription factors Sp1, AP1, AP2 and CREB
[5,7]. However, the mechanisms that regulate expression
of this gene are still obscure. Disease-producing muta-
tions in genes encoding transcription factors have been
described in both mice and humans [18].
In the nuclear extracts from human thyroid tissue ana-
lyzed in the present study DNA-protein binding was de-
tectable in two different sequences of the regulatory
region of the NIS gene and it was compatible with DNA
binding activity of the nuclear transcription factors AP2
and Sp1. Gel retardation analysis demonstrated signifi-
cantly greater binding of both AP2 and Sp1 in nuclear ex-
tracts from tumoral thyroid tissue with respect to normal
thyroid tissue. These data were supported by immunob-
lotting analysis, which showed that the immunological
characteristics of the two proteins detected in the nuclear
extracts were identical to those of AP2 and Sp1. In agree-
ment with our findings, Xu and coworkers reported that
the Sp1 binding activity to the hNIS promoter was higher
in some thyroid papillary carcinoma cell lines than in the
normal FRTL-5 cells [11]. These observations indicate that
interactions of trans-acting factors with sequences of the
NIS promoter may be crucial for proper expression of the
NIS. Moreover, they suggest that alterations in the expres-
sion of these nuclear proteins may cause decreased NIS ex-
pression and reduced I- uptake in patients with thyroid
cancer.
Conclusion
We believe that this is the first report describing a quanti-
tative abnormality in trans-acting factors which affect the
levels of expression of the NIS gene. Further studies will be
necessary to determine the prevalence of this defect in a
large number of thyroid tumors.
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